The sodium‐glucose co‐transporter‐2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac <scp>mTOR</scp> signalling, endoplasmic reticulum stress and apoptosis-Reference-Cited by-同舟云学术

The sodium‐glucose co‐transporter‐2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis

Published:2022-08 Issue:11 Volume:24 Page:2263-2272
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Moellmann Julia¹^ORCID,Mann Pascal A.¹,Kappel Ben A.¹,Kahles Florian¹,Klinkhammer Barbara M.²,Boor Peter²³,Kramann Rafael³⁴,Ghesquiere Bart⁵⁶,Lebherz Corinna¹,Marx Nikolaus¹,Lehrke Michael¹^ORCID

Affiliation:

1. Department of Internal Medicine I University Hospital Aachen, RWTH Aachen University Aachen Germany

2. Institute of Pathology, University Hospital Aachen RWTH Aachen University Aachen Germany

3. Department of Nephrology and Clinical Immunology RWTH Aachen University Aachen Germany

4. Institute of Experimental Medicine and Systemsbiology, University Hospital Aachen RWTH Aachen University Aachen Germany

5. VIB Metabolomics Expertise Center VIB Center for Cancer Biology Leuven Belgium

6. KU Leuven Metabolomics Expertise Center, Department of Oncology Katholieke Universiteit Leuven Leuven Belgium

Funder

Deutsche Herzstiftung

Deutsche Forschungsgemeinschaft

European Research Council

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14814

Reference26 articles.

1. Metabolic remodelling in heart failure

2. Targeting myocardial substrate metabolism in heart failure: potential for new therapies

3. Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition?

4. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure

5. The Failing Heart Relies on Ketone Bodies as a Fuel

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis;Scientific Reports;2024-09-02

2. SGLT2 inhibitors: how do they affect the cardiac cells;Molecular and Cellular Biochemistry;2024-08-19

3. Implications of endoplasmic reticulum stress and autophagy in aging and cardiovascular diseases;Frontiers in Pharmacology;2024-07-25

4. Examining the Impact of Ertugliflozin on Cardiovascular Outcomes in Patients with Diabetes and Metabolic Syndrome: A Systematic Review of Clinical Trials;Pharmaceuticals;2024-07-11

5. Progenitor Cell Function and Cardiovascular Remodelling Induced by SGLT2 Inhibitors;Frontiers in Bioscience-Landmark;2024-04-09